We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Leica Microsystems' US Acquisition Expands Histopathology Range

By Labmedica staff writers
Posted on 19 May 2008
In a move that further advances its strong global position in the histopathology field, Leica Microsystems announced the acquisition of the assets of US-based Coretech Holdings. More...
The acquired concern is to become a business unit within Leica Microsystems' Biosystems Division, and will be renamed Leica Biosystems St. Louis, LLC. Terms of the transaction were not disclosed.

Composed of a group of strong brands including McCormick Scientific, The Vibratome Company, Paraplast embedding media, TurbOflow II histology cassettes and myNeuroLab.com, Coretech (St. Louis, MO, USA) provides an extensive range of systems, instruments, reagents, and consumables for the clinical and research histology laboratory.

According to Doug Martin, formerly CEO of Coretech Holdings and now Vice President & General Manager of Leica Biosystems St. Louis, LLC, The synergies created by combining the Coretech products and team with those of Leica Microsystems are considerable. Both companies will quickly leverage an improved product offering for our customers and expand our ability to service their needs.

Anne De Greef-Safft, President of Leica Microsystems' Biosystems Division added, With this acquisition, Leica Microsystems continues to broaden and strengthen the product line we offer our customers. The benefit to customers is that they now have a single partner to come to for all their histology equipment, reagent, and consumable needs. Having internal R&D, as well as manufacturing capabilities for the instrument and their associated reagents and consumables allows us to better optimize the entire system, leading to higher quality and more consistent results for our customers.

Leica Microsystems (Wetzlar, Germany) is a leading global developer and producer of precision optical systems for the analysis of microstructures. The company manufactures a broad range of products requiring microscopic imaging, measurement, and analysis, and offers system solutions for life sciences including biotechnology and medicine, R&D of raw materials, and industrial quality assurance. Leica Microsystems is represented in over 100 countries with 9 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers.


Related Links:
Coretech
Leica Microsystems

New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.